Tech Center 1600 • Art Units: 1654 1656
This examiner grants 85% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18024871 | METHODS OF USING POLYMERIZED HUMAN SERUM ALBUMIN | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17920231 | EPHA4 TARGETING COMPOUNDS AND METHODS OF USE THEREOF | Non-Final OA | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 17058887 | TARGETING ANABOLIC DRUGS FOR ACCELERATED FRACTURE REPAIR | Final Rejection | Purdue Research Foundation |
| 17786157 | STRUCTURALLY-STABILIZED GLUCAGON-LIKE PEPTIDE 1 PEPTIDES AND USES THEREOF | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 18018238 | Lysosomal Targeting Molecules Comprising Knottin Peptides And Related Compositions And Methods | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18488532 | MRNA THERAPEUTIC COMPOSITIONS | Non-Final OA | Nutcracker Therapeutics, Inc. |
| 17794229 | AFFINITY PEPTIDE CONJUGATED WITH ANTIOXIDANT FOR PROTECTION OF PROTEINS FROM OXIDATION | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA |
| 18258102 | G PROTEIN PEPTIDOMIMETICS | Non-Final OA | VRIJE UNIVERSITEIT BRUSSEL |
| 18555234 | ANTIMICROBIAL PEPTOID HAVING IMPROVED SELECTIVITY AND ANTIMICROBIAL COMPOSITION COMPRISING SAME | Non-Final OA | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 18254459 | CYCLIC PEPTIDES WITH ANTIMICROBIAL PROPERTIES | Non-Final OA | Northeastern University |
| 18033229 | MOLECULAR DESIGNS OF GLUCOSE-RESPONSIVE AND GLUCOSE-CLEAVABLE INSULIN ANALOGUES | Non-Final OA | THE TRUSTEES OF INDIANA UNIVERSITY |
| 17774892 | TARGETED DELIVERY OF NANOCARRIER-CONJUGATED DOXORUBICIN | Non-Final OA | UNIVERSITY OF MIAMI |
| 18549938 | LIQUID NUTRITIONAL COMPOSITION SUITABLE FOR MUSCLE FUNCTION | Non-Final OA | N.V. Nutricia |
| 17817777 | Composition and Methods for Selective Degradation of Engineered Proteins | Final Rejection | Celgene Corporation |
| 18273200 | NOVEL BICYCLIC PEPTIDES | Non-Final OA | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH |
| 17923394 | ABERRANT POST-TRANSLATIONAL MODIFICATIONS (PTMS) IN METHYL- AND PROPIONIC ACIDEMIA AND A MUTANT SIRTUIN (SIRT) TO METABOLIZE PTMS | Non-Final OA | The U.S.A., as represented by the Secretary, Department of Health and Human Services |
| 17909907 | GLP RECEPTOR AGONISTS | Non-Final OA | NXERA PHARMA UK LIMITED |
| 18268139 | USE OF GLP-2 ANALOGUES IN PATIENTS WITH RENAL INSUFFICIENCY | Non-Final OA | Zealand Pharma A/S |
| 18280949 | TEMPERATURE SENSITIVE GEL DAMAGE REPAIR FORMULATION AND APPLICATION THEREOF | Non-Final OA | HUATONG FORTURN BIOPHARMACEUTICAL (SHANDONG) CO., LTD |
| 18273181 | Use Of Naturally Occurring Cyclic Peptides For Treatment Of SARS-COV-2 Infection | Non-Final OA | The University of Southern California |
| 18146396 | COMPOSITION AND METHOD FOR WOUND HEALING AND REPAIR OF DAMAGED NERVES | Non-Final OA | PHARMAZZ, INC. |
| 17787274 | LIPOLYSIS COMPOSITION USING SURFACE-MODIFIED GAS-GENERATING NANOPARTICLES | Final Rejection | SUPERNOVA BIO CO., LTD. |
| 18269231 | PEPTIDES FOR THE TREATMENT OF RESPIRATORY INFECTIONS OF VIRAL ORIGIN | Non-Final OA | CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA |
| 18268951 | CYCLIC PEPTIDES AND USES THEREOF | Non-Final OA | PREVECEUTICAL MEDICAL INC. |
| 18256628 | MACROPHAGE ACTIVATOR | Non-Final OA | SAISEI PHARMA CO., LTD. |
| 18037447 | TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES | Non-Final OA | THE BOOTS COMPANY PLC |
| 18031298 | THERAPEUTIC TREATMENT | Non-Final OA | UNIVERSITÄT ZU KÖLN |
| 18040398 | TOPICAL AND PARENTERAL USE AND ADMINISTRATION OF SELF-ASSEMBLING AMPHIPHILIC PEPTIDE HYDROGELS | Non-Final OA | GEL4MED, INC. |
| 17924986 | Therapeutic Potential of Peptides from the "Netrin-Like" Domain of the FRZB Protein | Final Rejection | CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE NANCY |
| 17923744 | PEPTIDE FOR PREVENTION OR TREATMENT OF COVID-19 | Non-Final OA | APEPTICO FORSCHUNG UND ENTWICKLUNG GMBH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy